Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Effectiveness and safety of droperidol in a United States emergency department.

< BACK TO ARCHIVE


2020 Jul


Am J Emerg Med


http://www.ncbi.nlm.nih.gov/pubmed/31831345?dopt=Abstract


38


7

Effectiveness and safety of droperidol in a United States emergency department.

Authors

Effectiveness and safety of droperidol in a United States emergency department.
Gaw CM, Cabrera D, Bellolio F, Mattson AE, Lohse CM, Jeffery MM
Am J Emerg Med. 2020 Jul; 38(7):1310-1314.
PMID: 31831345.

Abstract

Droperidol is a dopamine receptor antagonist that functions as an analgesic, sedative, and antiemetic. In 2001, the U.S. Food and Drug Administration required a black box warning in response to case reports of QT prolongation and potential fatal arrhythmias. The aim of this study was to evaluate the effectiveness and safety of droperidol in patients presenting to a United States Emergency Department (ED).
Read This Paper